Introduction {#Sec1}
============

Breast cancer is the most common cancer in women. In 2008, 1.38 million new cases of breast cancer were diagnosed worldwide, and there were over 458,000 deaths \[[@CR1]\]. Over the last 25 years, the incidence of breast-cancer related deaths has declined in the USA and parts of Europe, mostly owing to improved detection and treatment \[[@CR2]\]. However, survival in patients with breast cancer depends heavily on the stage of the tumour, with US statistics demonstrating a 98 % survival rate at 5 years in patients with non-invasive disease, such as ductal carcinoma in situ, which decreases to 24 % in patients with metastatic disease \[[@CR3]\]. Unfortunately, approximately one-third of women with early-stage breast cancer will eventually develop metastatic disease \[[@CR4]\], and metastatic breast cancer is currently incurable.

The goals of therapy in patients who have metastatic disease focus on prolonging survival and maintaining quality of life by controlling symptoms and minimizing toxicity. Treatment choice in breast cancer is influenced by the hormone receptor and human epidermal growth factor receptor 2 (HER2) status of the tumour, and patients with metastatic disease may benefit from treatment tailored to their individual genotype status. Several targeted therapies are under development, but systemic chemotherapy remains an important approach for patients with metastatic breast cancer, particularly in patients with hormone-refractory, hormone receptor-negative or rapidly progressing metastatic disease \[[@CR4], [@CR5]\].

This review provides an overview of chemotherapeutic agents for the treatment of metastatic breast cancer patients previously treated with anthracyclines and taxanes, focusing on a clinical evaluation of eribulin, the most recently approved agent for the treatment of metastatic breast cancer.

Chemotherapeutic Agents for Metastatic Breast Cancer {#Sec2}
====================================================

Breast cancer can be treated with chemotherapeutic agents from various classes, including antimicrotubule agents such as taxanes and eribulin, anthracyclines and antimetabolites \[[@CR6]--[@CR9]\]. Taxanes and anthracyclines are commonly used for first-line treatment of breast cancer, but development of drug resistance to these agents upon tumour recurrence is common. Despite the high level of resistance in recurrent breast cancer, studies have shown that third-line treatments can extend the time of disease control in a significant number of patients \[[@CR10]\]. Agents used for treatment of women with metastatic breast cancer who have been previously treated with anthracyclines and taxanes include eribulin, ixabepilone and capecitabine (Table [1](#Tab1){ref-type="table"}) \[[@CR11]--[@CR13]\].Table 1Chemotherapeutic agents for metastatic breast cancer: mechanism of action \[[@CR11]--[@CR13], [@CR17]--[@CR21]\]Drug classAgentsMechanism of actionAnthracyclinesDoxorubicin, epirubicinDNA intercalation and induction of cell deathAntimetabolitesCapecitabine, S-1, gemcitabineInhibits processes required for DNA synthesisAntimicrotubule agentsPaclitaxelStabilizes microtubules by inhibiting the shortening of microtubulesDocetaxelIxabepiloneEribulinInhibits microtubules by suppressing microtubule growth at the plus endVinorelbineInhibits microtubules by inhibiting the polymerization of tubulin dimers and depolymerizationPlatinum analoguesCarboplatin, cisplatinInduces DNA adduct formation and cell deathTopoisomerase inhibitorIrinotecanInterferes with DNA coiling to inhibit transcription and replication

Whereas antimicrotubule agents such as taxanes and eribulin all act by sending the cell into apoptosis via mitotic arrest after tubulin binding, the mechanism of action of eribulin is unique amongst the antimicrotubule agents \[[@CR14], [@CR15]\]. Whereas paclitaxel inhibits microtubule shortening \[[@CR14]\], eribulin prevents microtubule growth \[[@CR15]\]. Eribulin binds to the plus ends of the microtubule \[[@CR16]\], inhibiting microtubule dynamics by suppressing microtubule polymerization \[[@CR15]\]. This in turn sequesters tubulin into non-functional aggregates \[[@CR15]\].

Anthracyclines such as doxorubicin and epirubicin induce DNA intercalation and apoptosis of tumour cells \[[@CR17]\]. Antimetabolites, which include capecitabine and gemcitabine, inhibit processes required for DNA synthesis \[[@CR11], [@CR18]\] and the oral 5-fluorouracil (5-FU) analogue S-1 (a combination of the prodrug tegafur and two modulators of 5-FU) acts following its biotransformation to cytotoxic nucleotides \[[@CR19]\]. Other choices for breast cancer treatment include platinum analogues such as carboplatin and cisplatin, which induce DNA adduct formation \[[@CR20]\], and irinotecan, which inhibits DNA synthesis via an interaction with topoisomerase I \[[@CR21]\].

Several factors to be considered when selecting agents for patients previously treated with anthracyclines and taxanes include pre-treatment history, previous response, residual toxicity and tumour aggressiveness. The standard regimen for metastatic breast cancer patients previously treated with anthracyclines and taxanes remains to be established.

Clinical and Pharmacological Evaluation of Eribulin {#Sec3}
===================================================

Pharmacological Properties {#Sec4}
--------------------------

Eribulin is a synthetic derivative of halichondrin B, a cell-cycle progression inhibitor found in marine sponges \[[@CR15]\]. Eribulin was approved for the treatment of metastatic breast cancer patients previously treated with anthracyclines and taxanes in the USA in 2010 \[[@CR22]\] and in Europe and Japan in 2011 \[[@CR23], [@CR24]\].

Phase I studies show that eribulin exhibits linear pharmacokinetics. In patients with advanced solid tumours, the peak drug plasma concentration was 44--528 ng/mL after single doses of eribulin of 0.25--4.0 mg/m^2^ \[[@CR25]\]. Eribulin does not accumulate after multiple doses and is rapidly and extensively distributed \[[@CR25]\]. In a phase I study of eribulin in patients with advanced solid tumours, the mean half-life was 46.5 h \[[@CR25]\]. A similarly prolonged half-life was seen in a dose-ranging study of eribulin in Japanese patients with refractory solid tumours (36.4--59.9 h with doses of 0.7--2.0 mg/m^2^ (Table [2](#Tab2){ref-type="table"}) \[[@CR26]\]. Eribulin exhibited triphasic pharmacokinetics with a long terminal half-life, high volume of distribution and low urinary clearance. This study was conducted to investigate higher doses of eribulin and to determine the dose-limiting toxicities (DLT), the recommended dose and the maximum tolerated dose in Japanese patients. As expected, the pharmacokinetic parameters of *C*~max~ and area under the drug concentration--time curve (AUC) of eribulin increased with each dose level (Table [2](#Tab2){ref-type="table"}), and an increase in dose correlated with the incidence of adverse events \[[@CR26]\]. This phase I study established the recommended dose of 1.4 mg/m^2^. Maximum tolerated dose (MTD) was 2.0 mg/m^2^ and the main DLT was neutropenia, which was smoothly recovered and manageable. These observations suggest that eribulin-related adverse events can be managed by the appropriate dose modifications. On the basis of this study and others to be discussed below, dose delay or dose reduction to 1.1 and 0.7 mg/m^2^ is recommended upon the incidence of severe adverse events.Table 2Pharmacokinetic parameters and dose-limiting toxicities in the phase I study of eribulin in Japanese patients with advanced solid tumours \[[@CR26]\]Eribulin dose0.7 mg/m^2^ (*n* = 3)1.0 mg/m^2^ (*n* = 3)1.4 mg/m^2^ (*n* = 6)2.0 mg/m^2^ (*n* = 3)*C* ~max~, ng/mL288.5 ± 43.0380.6 ± 52.9519.4 ± 107.2717.6 ± 104.3AUC~0--∞~, ng·h/mL299.2 ± 124.5379.6 ± 65.2672.7 ± 113.71,370.1 ± 282.2*t* ~1/2~, h36.4 ± 11.242.9 ± 10.939.4 ± 8.359.9 ± 13.4DLT^a^, *n* (%)002 (33)^b^3 (50)^c^All data provided as mean ± standard deviation unless otherwise stated*AUC* ~*0--∞*~ area under the drug concentration--time curve from time 0 to infinity, *DLT* dose-limiting toxicities, *C* ~*max*~ peak drug concentration, *h* hours, *n* number, *t* ~1/2~ terminal half-life^a^Assessed in cycle 1 of eribulin treatment^b^Grade 4 neutropenia and grade 3 febrile neutropenia resulting in omission of the day 8 dose^c^Grade 4 neutropenia, grade 3 neutropenia and grade 3 febrile neutropenia resulting in omission of the day 8 dose

Clinical Properties {#Sec5}
-------------------

### Phase II Studies {#Sec6}

In phase II studies, eribulin exhibited efficacy in patients with metastatic breast cancer who had previously been heavily treated with other chemotherapeutic agents. Two open-label, single-arm studies investigated the efficacy and tolerability of eribulin in 103 and 291 patients with metastatic breast cancer previously treated with an anthracycline and a taxane (study 201; NCT00097721) \[[@CR27]\] or an anthracycline, taxane and capecitabine (study 211; NCT00246090) \[[@CR28]\], respectively. In the per-protocol population of the smaller study (*n* = 87), eribulin had an overall response rate of 11.5 %, whereas patients in the larger study had an overall response rate of 9.3 %; in both studies, all responses were considered partial \[[@CR27], [@CR28]\]. In the smaller study, the clinical benefit rate, which includes patients demonstrating a response and those with stable disease for more than 6 months, was 17.2 % \[[@CR27]\]. Patients had a median progression-free survival of 2.6 months in both studies, and median overall survival was 9.0 months \[[@CR27]\] and 10.4 months \[[@CR28]\] (Table [3](#Tab3){ref-type="table"}).Table 3Phase II studies of eribulin in patients with metastatic breast cancer who have previously received an anthracycline and taxane201 \[[@CR27]\]211 \[[@CR28]\]221 \[[@CR29]\]*n*10329180Prior chemotherapyAny prior regimen of chemotherapy with A and T (median 4)2--5 prior regimens of chemotherapy with A, T and CAP (median 4)≤3 prior regimens of chemotherapy including A and T (median 3)Dosing schedule1.4 mg/m^2^ IV inf\
d1 + 8 + 15 q4w\
1.4 mg/m^2^ IV inf d1 + 8\
q3w1.4 mg/m^2^ IV inf d1 + 8\
q3w1.4 mg/m^2^ IV inf d1 + 8\
q3wTumour response PR (%)11.5 \[total\]\
10.2 \[q4w cohort\]\
14.3 \[q3w cohort\]9.321.3 SD, %11.5 \[total\]\
10.2 \[q4w cohort\]\
14.3 \[q3w cohort\]46.542.5 ORR^a^ (%)11.5 \[total\]\
10.2 \[q4w cohort\]\
14.3 \[q3w cohort\]9.321.3 CBR^b^ (%)17.2 \[total\]\
11.9 \[q4w cohort\]\
28.6 \[q3w cohort\]17.127.5 Median duration of response (months)5.64.13.9 Median PFS (months)2.62.63.7 Median OS (months)9.010.411.1*A* anthracycline, *CAP* capecitabine, *CBR* clinical benefit rate, *d* day, *IV inf* intravenous infusion, *ORR* objective response rate, *OS* overall survival, *PFS* progression-free survival, *PR* partial response, *qXw* every*X* weeks, *SD* stable disease, *T* taxane^a^Objective response rate = complete response + partial response^b^Clinical benefit rate = complete response + partial response + stable disease ≥6 months

In Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane (study 221) \[[@CR29]\], eribulin appears to have a better efficacy than that observed in the others mentioned in Table [3](#Tab3){ref-type="table"}. This open-label study of 80 patients who received 1.4 mg/m^2^ of eribulin demonstrated that eribulin had an objective clinical response rate of 21.3 % and a clinical benefit rate of 27.5 % in this patient population. However, this improved efficacy may be in part due to patient characteristics. In the previous two studies, patients had received a median of four previous regimens of chemotherapy containing an anthracycline plus a taxane and an anthracycline, taxane and capecitabine combination, respectively. In study 221, patients had received a median of three previous regimens of chemotherapy containing an anthracycline and a taxane. When the objective response rate was assessed according to the number of previous chemotherapy regimens in the metastatic setting, a higher response rate of 36 % was observed in patients who had no or one previous regimen, and patients who had a median of two or more previous regimens had a decrease in response. In addition, further investigation is needed to evaluate whether pharmacogenetic variation contributes to eribulin efficacy and safety, because P-glycoprotein (P-gp) may be involved in eribulin disposition and polymorphism of*MDR1*, the gene encoding P-gp, affects chemotherapeutic outcome.

### Phase III Studies {#Sec7}

Two phase III studies have investigated the efficacy of eribulin in metastatic breast cancer. EMBRACE (study 305; NCT00388726) compared eribulin with the physician's choice of therapy in 762 patients, and another study compared eribulin with capecitabine in 1,102 women previously treated with no more than three regimens (study 301; NCT00337103) \[[@CR30], [@CR31]\].

The encouraging results of the three phase II trials discussed previously led to the initiation of the phase III EMBRACE study---a randomized, open-label, multinational study that investigated the efficacy of eribulin in heavily pre-treated women with locally recurrent or metastatic breast cancer \[[@CR30]\]. Patients were required to have previously received between two and five chemotherapy regimens including an anthracycline and a taxane, and two or more regimens for locally recurrent or metastatic breast cancer. A dosage of 1.4 mg/m^2^ of eribulin was administered intravenously over 2--5 min on days 1 and 8 of a 21-day treatment cycle, and patients in the treatment of physician's choice (TPC) group received single-agent chemotherapy, cancer treatment-approved biological treatment, hormonal therapy, radiotherapy or symptomatic treatment \[[@CR30]\]. The proposed TPC was chosen for each patient and confirmed before central randomization. In the TPC arm, 96 % received chemotherapy including vinorelbine, gemcitabine and capecitabine, 4 % received hormonal therapy but no patient received supportive care alone. The primary endpoint of the EMBRACE study was overall survival.

Eribulin significantly increased the median overall survival of patients compared with the TPC group (13.1 vs 10.6 months; hazard ratio \[HR\] 0.81, 95 % confidence interval \[CI\] 0.66, 0.99; *p* = 0.041; Table [4](#Tab4){ref-type="table"}). In the eribulin treatment group there were 274 deaths (54 %) compared with 148 (58 %) in the TPC group; corresponding 1-year survival rates were 53.9 and 43.7 %, respectively \[[@CR30]\]. The median progression-free survival (assessed by investigator review) was also significantly prolonged with eribulin treatment (HR 0.76; 95 % CI 0.64, 0.90; *p* = 0.002; Table [4](#Tab4){ref-type="table"}); however, when assessed by independent review the difference in progression-free survival no longer appeared significant (HR 0.87; 95 % CI 0.71, 1.05; *p* = 0.137; Table [4](#Tab4){ref-type="table"}).Table 4Phase III studies of eribulin in patients with metastatic breast cancer who have previously received an anthracycline and taxane305 (EMBRACE) \[[@CR30]\]301 \[[@CR31]\]EribulinTPCEribulinCAP*n*508254554548Median OS, months13.1\*10.615.9^†^14.5Independent reviewInvestigator reviewIndependent reviewInvestigator reviewIndependent reviewIndependent reviewMedian PFS, months3.73.6^‡^2.22.24.14.2Tumour response (%) CR1\<100NRNR PR121357NRNR SD44474545NRNR ORR^a^12^§^13^¶^571112 CBR^b^23281720NRNR*CAP* capecitabine, *CBR* clinical benefit rate, *CR* complete response, *NR* not reported in meeting abstract, *ORR* objective response rate, *OS* overall survival, *PFS* progression-free survival, *PR* partial response, *SD* stable disease, *TPC* treatment of physician's choice\* *p* = 0.041 vs TPC; ^†^ *p* = 0.056 vs CAP; ^‡^ *p* = 0.002 vs TPC; ^§^ *p* = 0.002 vs TPC; ^¶^ *p* = 0.028 vs TPC^a^Objective response rate = complete response + partial response^b^Clinical benefit rate = complete response + partial response + stable disease ≥6 months

In patients with measurable disease, significantly more patients had an objective response (assessed by independent review) in the eribulin treatment group (12 %) compared with the TPC group (5 %; *p* = 0.002) (Table [4](#Tab4){ref-type="table"}). The clinical benefit rates were 23 % (95 % CI 18.9, 26.7) for eribulin and 17 % (12.1, 22.5) in the TPC group.

On the basis of the demonstration of a statistically significant prolongation of overall survival, eribulin mesylate was approved by the US Food and Drug Administration (FDA). This approval highlights the appropriate use of an innovative trial design and shows that improvement in overall survival is an achievable endpoint in the setting of advanced breast cancer.

Study 301 was a phase III, randomized, open-label, multinational study that also investigated the efficacy of eribulin in heavily pre-treated women with locally recurrent or metastatic breast cancer \[[@CR31]\]. Patients were required to have previously received at most three chemotherapy regimens (at most two for advanced disease) with each regimen including an anthracycline or a taxane. Patients were randomized to either 1.4 mg/m^2^ of eribulin (administered intravenously over 2--5 min on days 1 and 8 of a 21-day treatment cycle) or oral capecitabine (1,250 mg/m^2^ twice daily on days 1--14 of a 21-day treatment cycle) \[[@CR31]\]. The co-primary endpoints of study 301 were overall survival and progression-free survival.

Like the EMBRACE study, eribulin increased the median overall survival of patients compared with capecitabine (15.9 vs 14.5 months; HR 0.88, 95 % CI 0.77, 1.00; *p* = 0.056; Table [4](#Tab4){ref-type="table"}), although this difference was not statistically significant. In contrast, the median progression-free survival of both arms was almost identical (assessed by independent review) (Table [4](#Tab4){ref-type="table"}). Similarly, in patients with measurable disease, there was no apparent difference in the proportion of patients who had an objective response rate (assessed by independent review) in the eribulin treatment group (11 %) compared with capecitabine (12 %) (Table [4](#Tab4){ref-type="table"}).

Pre-specified exploratory analyses of the phase III trials discussed here suggest that particular patient subgroups may have greater therapeutic benefit with eribulin (Table [5](#Tab5){ref-type="table"}). In particular, patients who are HER2 negative, oestrogen receptor negative or triple negative had significantly longer overall survival rates with eribulin treatment compared with capecitabine in study 301, as presented at the 2012 San Antonio Breast Cancer Symposium (Table [5](#Tab5){ref-type="table"}) \[[@CR31], [@CR32]\]. However, although overall survival was prolonged in certain subgroups of patients receiving eribulin in study 301, the objective response rate and progression-free survival were similar between eribulin and capecitabine treatment in all subgroups assessed. This may be due to several factors: (1) patients receiving eribulin were allowed to cross over to capecitabine, whereas patients receiving capecitabine were allowed to receive eribulin less frequently, owing to the limited market access prior to approval; (2) more patients receiving eribulin may maintain better quality of life and accept a subsequent chemotherapy regimen owing to its lower toxicity; or (3) eribulin might have a promoting effect on the clinical activity of the subsequent chemotherapy regimen through the alteration of tumour phenotype, although this possibility is currently just speculation. Further basic research and clinical investigations focusing on these ideas are warranted to determine the possible cause of the increase in overall survival with eribulin.Table 5Subgroup analysis of overall survival in the phase III studies of eribulin by human epidermal growth factor receptor 2 (HER2) and oestrogen receptor (ER) status305 (EMBRACE) \[[@CR30]\]301 \[[@CR31], [@CR32]\]OS (months)HR (95 % CI)OS (months)HR (95 % CI)EribulinTPCEribulinCAPTotal13.210.50.81 (0.66, 0.99)15.914.50.88 (0.77, 1.00)HER2+11.39.10.76 (0.47, 1.24)14.317.10.97 (0.69, 1.36)HER2−13.210.50.81 (0.64, 1.02)15.913.50.84 (0.72, 0.98)ER+13.811.40.81 (0.63, 1.04)18.216.80.90 (0.74, 1.09)ER−10.27.80.78 (0.54, 1.13)14.410.50.78 (0.64, 0.96)TN9.57.00.71 (0.46, 1.10)14.49.40.70 (0.55, 0.91)*CAP* capecitabine, *ER* oestrogen receptor, *HER2* human epidermal growth factor receptor 2, *TN* triple negative, *TPC* treatment of physician's choice

Tolerability {#Sec8}
------------

Phase I studies have suggested that eribulin doses of 1.0--2.0 mg/m^2^ result in a manageable toxicity profile, and as a result the approved dosage of eribulin is a 2--5 min infusion of 1.4 mg/m^2^ on days 1 and 8 of a cycle lasting 21 days \[[@CR12], [@CR25], [@CR26], [@CR33]\]. Eribulin continued to exhibit an acceptable toxicity profile in both phase II \[[@CR27]--[@CR29]\] and phase III \[[@CR30], [@CR31]\] studies.

Consistent with the findings of the phase II trials \[[@CR27]--[@CR29]\], in the EMBRACE trial adverse events were reported in 497 (99 %) patients receiving eribulin and 230 (93 %) patients receiving the TPC; of these, 126 (25 %) and 64 (26 %) patients reported serious adverse events \[[@CR30]\]. The most common adverse events in either treatment group were asthenia or fatigue (54 and 40 % of patients receiving eribulin and the TPC, respectively) and neutropenia (52 and 30 %, respectively). More patients receiving eribulin reported grade 3 or 4 neutropenia (45 vs 21 %), leukopenia (14 vs 6 %) or peripheral neuropathy (8 vs 2 %) \[[@CR30]\].

Peripheral neuropathy was the most common adverse event leading to discontinuation of eribulin in the EMBRACE trial, with 24 (5 %) patients discontinuing treatment \[[@CR30]\]. However, the incidence of peripheral neuropathy was similar in the eribulin treatment group (overall, 35 % of patients; grade 3, 8 %; grade 4, \<1 %) and the taxane (overall, 45 % of patients; grade 3, 5 %; no grade 4) treatment group \[[@CR30]\].

Similarly, the adverse events reported in study 301 were consistent with the previously known side effects of eribulin \[[@CR31]\]. Adverse events were reported in 94.1 % of patients receiving eribulin and 90.5 % of patients receiving capecitabine; 17.5 and 21.1 % of patients reported serious adverse events \[[@CR31]\]. More patients receiving eribulin had neutropenia (54 vs 16 %) and leukopenia (31 vs 10 %); however, the incidence of anaemia, thrombocytopenia and febrile neutropenia was similar between treatment groups \[[@CR31]\]. Other common adverse events reported in patients receiving eribulin included alopecia (35 %), nausea (22 %), fatigue (17 %) and asthenia (15 %). Peripheral sensory neuropathy was observed in 13 % of patients (grade 3, 4 % of patients; no grade 4) \[[@CR31]\].

Ongoing Studies of Eribulin and Other Agents {#Sec9}
============================================

There are several ongoing studies investigating eribulin in breast cancer, including those investigating eribulin in the neo-adjuvant \[[@CR34]--[@CR38]\] and adjuvant setting \[[@CR39]--[@CR41]\], in patients with metastatic disease \[[@CR42]--[@CR49]\], and in combination with other anti-cancer agents \[[@CR34], [@CR37]--[@CR40], [@CR42], [@CR43], [@CR45]--[@CR49]\] (Table [6](#Tab6){ref-type="table"}).Table 6Ongoing clinical studies investigating eribulin in patients with breast cancerStudy designTreatmentsStudy identifierRegimen settingDisease typeTrial details (estimated enrolment)Primary endpointNon-metastatic disease Neo-adjuvantHER2+Phase I/II, OL, SG (56)pCREribulin + carboplatin, trastuzumabNCT01388647 \[[@CR34]\]HER2−Phase II, OL, SG (47)pCREribulin then dose-dense doxorubicin + cyclophosphamideNCT01498588 \[[@CR35]\]HER2−Phase II, R, PG, OL (152)pCREribulin then FAC vs paclitaxel then FECNCT01593020 \[[@CR36]\]HER2−Phase II, R, PG, OL (76)pCREribulin + cyclophosphamide vs docetaxel + cyclophosphamideNCT01527487 \[[@CR37]\]TNPhase II, SG, OL (30)pCREribulin + carboplatinNCT01372579 \[[@CR38]\] AdjuvantTN, HER2+, HER2−Phase II, PG, OL (148)2-year DFSEribulin or eribulin + trastuzumab in patients who do not achieve pCR following neo-adjuvant chemotherapyNCT01401959 \[[@CR39]\]ER+Phase II, SG, OL (67)FeasibilityEribulin + capecitabineNCT01439282 \[[@CR40]\]NSPhase II, SG, OL (80)FeasibilityDose-dense doxorubicin + cyclophosphamide then eribulinNCT01328249 \[[@CR41]\]Metastatic disease First-lineHER2+Phase II, SG, OL (52)ORREribulin + trastuzumabNCT01269346 \[[@CR42]\] First-lineHER2−Phase II, SG, OL (52)ORREribulinNCT01268150 \[[@CR44]\] Second-lineHER2−Phase II, R, PG, OL (141)PFSEribulin +/− ramucirumabNCT01427933 \[[@CR45]\] Second-lineTNPhase I/II SG, OL (80)MTD, PFSEribulin + PLX 3397NCT01596751 \[[@CR46]\] Fourth-lineNSPhase I/II, R, OL (116)Tolerability, responseEribulin + capecitabineNCT01323530 \[[@CR47]\] NSHER2+Phase II, R, PG, OL (80)TTP, tolerabilityEribulin + lapatinibNCT01534455 \[[@CR43]\] NSNSPhase I/II, SG, OL (58)MTD, CBREribulin + cyclophosphamideNCT01554371 \[[@CR48]\] NSNSPhase I, SG, OL (54)Tolerability, AUC, *C* ~max~, QT timeEribulin + sorafenibNCT01585870 \[[@CR49]\]*AUC* area under the drug concentration--time curve, *CBR* clinical benefit rate, *C* ~*max*~ peak drug concentration, *DFS* disease-free survival, *ER* oestrogen receptor, *FAC* fluorouracil + doxorubicin + cyclophosphamide, *FEC* fluorouracil + epirubicin + cyclophosphamide, *HER2* human epidermal growth factor receptor 2, *MTD* maximum tolerated dose, *NS* not specified, *OL* open label, *ORR* objective response rate, *pCR* pathological complete response rate, *PFS* progression-free survival, *PG* parallel group, *R* randomized, *SG* single group, *TN* triple negative, *TTP* time to progression

So far, preliminary results of three studies of eribulin have been presented and suggest that eribulin would be efficacious and well tolerated as a treatment in other breast cancer populations. Preliminary results of two ongoing clinical trials that are investigating eribulin as first-line therapy either as monotherapy (NCT01268150) \[[@CR50]\] or combination therapy (NCT01269346) \[[@CR51]\] were presented at the 2012 San Antonio Breast Cancer Symposium. These results showed that as first-line therapy for patients with locally recurrent or metastatic breast cancer, eribulin appears to have anti-tumour activity and an acceptable safety profile, both when given as monotherapy and in combination with trastuzumab \[[@CR50], [@CR51]\].

The treatment of early-stage breast cancer with eribulin is also being investigated (NCT01328249) and preliminary results of this trial were presented at the 2012 San Antonio Breast Cancer Symposium \[[@CR52]\]. This study, which is investigating the efficacy and safety of adjuvant eribulin in patients with early-stage breast cancer who have received dose-dense doxorubicin and cyclophosphamide, suggests that eribulin has an acceptable safety profile in this patient group.

In addition to eribulin, several novel cytotoxic chemotherapies have been evaluated in clinical trials (Table [7](#Tab7){ref-type="table"}) and encouraging results have been reported \[[@CR53], [@CR54]\]. Traditional taxanes have large, complex molecular structures with hydrophobic and water-insoluble properties which require the drug be prepared with a toxic solvent, limiting the drug's clinical use. Therefore, many clinical studies investigating novel solvent-free formulations are ongoing. Novel solvent-free taxane formulations include nanoparticle albumin-bound (nab)--paclitaxel, cationic liposomal paclitaxel (EndoTAG-1) and paclitaxel poliglumex (paclitaxel bound to a biodegradable poly-[l]{.smallcaps}-glutamic acid) (reviewed by Villanueva et al. \[[@CR54]\]). Nab--paclitaxel is already available for breast cancer and is taking the place of solvent-based paclitaxel. Novel taxanes including larotaxel, tesetaxel and cabazitaxel and novel non-taxanes such as vinflunine and indibulin are being evaluated in phase II or III trials \[[@CR54]\]. In contrast to other antimicrotubule agents, tesetaxel is orally active and is not a substrate for P-gp \[[@CR54]\], and therefore may generate a new paradigm for breast cancer treatment. New agents of other classes are also in clinical development \[[@CR53]\]; these include liposomal doxorubicin, the antimetabolite pemetrexed, the platinum analogue satraplatin and the irinotecan prodrug NKTR-102.Table 7New chemotherapeutic agents for breast cancer recently approved or in clinical trials \[[@CR53], [@CR54]\]Drug classAgents (current phase in the trial)AnthracyclinesLiposomal doxorubicin (approved)AntimetabolitesPemetrexed (phase III)Antimicrotubule agents (new formulation)Nanoparticle albumin-bound (nab)--paclitaxel (approved)EndoTAG-1 (phase II)Paclitaxel poliglumex (phase II)Antimicrotubule agents (novel taxane)Larotaxel (phase II)Tesetaxel (phase II)Cabazitaxel (phase II)Antimicrotubule agents (novel non-taxane)Vinflunine (phase III)Indibulin (phase I/II)Platinum analoguesSatraplatin (phase II)Topoisomerase inhibitorNKTR-102 (phase III)

Conclusions {#Sec10}
===========

Because metastatic breast cancer remains incurable with currently available systemic therapies, novel approaches are crucial. Studies of eribulin have shown that the drug is effective in the treatment of previously treated metastatic breast cancer, and has an acceptable toxicity profile. Importantly, in the phase III EMBRACE study, eribulin treatment resulted in a survival advantage, a difficult endpoint to achieve with a single chemotherapeutic agent. An additional phase III study showed that eribulin has similar efficacy to capecitabine in women treated with no more than three prior therapies. Furthermore, pre-specified exploratory analyses suggest that particular patient subgroups may have greater therapeutic benefit with eribulin, and may warrant further study to explore the potential mechanisms behind these differences.

In addition, several classes of new cytotoxic chemotherapeutic agents are currently being evaluated in clinical trials and these promising agents may offer solutions to the difficult issues surrounding breast cancer. Considering the high efficacy of taxanes in breast cancer, new antimicrotubule agents including eribulin are expected to achieve the primary goals of systemic therapy, which are to prolong survival and improve quality of life, thereby realizing the wish of patients with an incurable disease to live longer and better.
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